2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)

3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (COMPLETED)

NCT06084481

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (M24-427)

NCT05950945

A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15) (DS8201-0001-CIS-MA)

NSW2060 - North Sydney - Mater Hospital (TERMINATED)

VIC3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (TERMINATED)

SA5000 - South Australia - GenesisCare St Andrews Hospital (TERMINATED)

WA6150 - Murdoch - Fiona Stanley Hospital (WITHDRAWN)

NCT05894239

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122)

NSW2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (WITHDRAWN)

VIC3168 - Clayton - Monash Medical Centre (COMPLETED)

WA6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (COMPLETED)

NANA (WITHDRAWN)

NCT05872295

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (IKS014-01)

NCT05867251

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (AVZO-021-1001)

NCT05735080

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01)

NCT05696626

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

NCT05646862

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy (INAVO121)

2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (COMPLETED)2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (WITHDRAWN)

QLD4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (COMPLETED)

NANA (WITHDRAWN)

NCT05636215

A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (CIBI354A101)

NSW2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)

VIC3168 - Clayton - Monash Medical Centre (COMPLETED)

QLD4575 - Sunshine Coast - Sunshine Coast University Private Hospital (COMPLETED)

NCT05216432

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (RLY-2608-101)

NCT05086692

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (ABILITY-1)

NCT04947189

4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer

NCT04895709

A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (CA052-002)

NCT04802759

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (CO42867)

NCT04606446

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (KAT6)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)

NCT04585750

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

NCT04085653

Managed Access Programs for BYL719, Alpelisib (CBYL719F12001M)

NCT03424005

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

ACTRN12626000621314

Not Applicable

Effect of Voyant Versus Diathermy for Haemostasis on post-surgical drainage and seroma in Breast Cancer Surgery: A Randomised Controlled Trial (VIBE)

ACTRN12625001015437

Not Applicable

EffIcacy of Intracavitary Manual Lymphatic Drainage as a Treatment for Vaginal Stenosis in Women With Sequelae of Post-Breast Cancer Treatment (none)

ACTRN12625000203459

An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (ENG19)

ACTRN12624001340527

A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer (PaxPlus-ABC)

ACTRN12622000016730

Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (HER2Pro-1B)

ACTRN12612000607875

Not Applicable

Can acupuncture compared with usual care reduce symptoms of lymphoedema in women recovering from breast cancer: a feasibility study

ACTRN12611000149965

Not Applicable

Feasibility of use of acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer (X09-0023)

ACTRN12609000904279

Study of molecular changes induced by treatment with bevacizumab in metastatic breast cancer

ACTRN12607000221459

A research study to evaluate the kinetics of mobilisation of blood stem cells and circulating tumour cells in response to docetaxel chemotherapy and pegfilgrastim.

ACTRN12607000176460

A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes - to compare the efficacy in terms of Overall Survival and Progression-Free Survival.

ACTRN12605000731695

Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer

ACTRN12605000377639

A randomised phase II study comparing the safety and efficacy of capecitabine with capecitabine and oral cyclophosphamide in patients with advanced breast cancer (Cyclox-II)

NCT05642949

Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors (MHB036C-CP001EN)

NCT03906331

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

oestrogen axis	37%
ER	32%
CDK4	25%
CDK6	22%
PD-1/PD-L1	19%
PI3Kalpha	18%
ERBB2	16%
PD-1	13%
PD-L1	10%
CDK4 selective	9%
Trop2	9%
mTOR	6%
mTORC1	6%
VEGFA	6%
CDK2	6%
VEGF	6%
KAT6A	5%
ERBB3	5%
EGFR	5%
mTORC2	4%
SMO	4%
KAT6	4%
AKT	4%
PARP	4%
Nectin4	3%
PI3K	3%
PARP1-selective	3%
B7H3	3%
GRPR	1%
hGIIA-vimentin	1%
Bcl2	1%
ER alpha	1%
FR-alpha	1%
MET	1%
IL-2	1%
CYP17A1	1%
androgen axis	1%
CCR8	1%
CDK7	1%
ER	1%
TP53	1%
TP53 Y220C	1%
CD40	1%
IL-6	1%
LIV1	1%
PI3K delta	1%
RET	1%

ARTICANZ - Beta (ver 0.91)

Search results

Breast / Breast - Metastatic

Filters